“…With the expected confirmation of Alex Azar – who is a former Eli Lilly executive – as the new Secretary of HHS, the Administration may initiate action. Azar has identified tackling high and rising drug costs as a top priority, stating that he would focus on competition, including a “robust generic market” and more competition…”
Source: Drug Pricing May Return to HHS Agenda in 2018 – By Sheila Burke, Amit Rao and Sam Sadle, January 23, 2018, Baker Donelson. Read the full piece here.
